Rheumatology Advance Access originally published online on March 2, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2004; 43: 704-711
Rheumatology Vol. 43 No. 6 © British Society for Rheumatology 2004; all rights reserved
Clinical |
Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy
Radiant Research, Dallas, Texas, 1 Stanford University Medical Center, Palo Alto, California and 2 Zynx Health, Los Angeles, California, USA.
Correspondence to: Stanley B. Cohen, Radiant Research, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235, USA. E-mail: Stanleycohen{at}radiantresearch.com
Objectives. To determine whether patient-reported outcomes may differentiate treatment response better than physician-reported outcomes for rheumatoid arthritis (RA) patients being treated with anakinra.
Methods. A meta-analysis was conducted using data obtained from three separate randomized controlled clinical trials (RCTs) (n = 1007). Outcomes from 6-month assessments were grouped into four categories: American College of Rheumatology (ACR) response criteria, patient-reported measures (patient-reported pain, patient global assessment, and assessment of physical function using the Health Assessment Questionnaire), physician-reported measures (tender and swollen joint counts and physician global assessment), and laboratory tests (C-reactive protein and erythrocyte sedimentation rate). Effect sizes were calculated using changes from baseline and pooled standard deviations for each of these types of outcome.
Results. Active treatment with anakinra was superior to placebo by ACR20 responses in all three RCTs. Effect sizes for patient-reported outcomes were greater than for physician-reported outcomes, and also greater than ACR20 in three of five anakinra cohorts. Across the RCTs, placebo responses were greater with physician-reported than with patient-reported outcomes. In the two studies evaluating patients with longer-standing disease, differences between pooled effect sizes for patient-reported and physician-reported outcomes were even more pronounced.
Conclusions. In three pivotal RCTs, active treatment with anakinra resulted in greater improvements in patient-reported than physician-reported outcomes compared with placebo. These observations confirm those previously reported from RCTs evaluating conventional DMARDs, demonstrating better discrimination of treatment effect with patient-reported outcomes.
KEY WORDS: Health status, Joints, Meta-analysis, Pain measurement, Randomized controlled trials, Recombinant interleukin-1 receptor antagonist, Rheumatoid arthritis, Treatment outcome.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. J. Gioe, D. Pomeroy, K. Suthers, and J. A. Singh Can patients help with long-term total knee arthroplasty surveillance? Comparison of the American Knee Society Score self-report and surgeon assessment Rheumatology, February 1, 2009; 48(2): 160 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Karonitsch, D Aletaha, M Boers, S Bombardieri, B Combe, M Dougados, P Emery, D Felson, J Gomez-Reino, E Keystone, et al. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis Ann Rheum Dis, October 1, 2008; 67(10): 1365 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Strand, A. Balbir-Gurman, K. Pavelka, P. Emery, N. Li, M. Yin, P. B. Lehane, and S. Agarwal Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years Rheumatology, December 1, 2006; 45(12): 1505 - 1513. [Abstract] [Full Text] [PDF]
|
|